A retrospective study to investigate the association between neutrophil to eosinophil ratio and outcome of patients with metastatic renal cell carcinoma treated with immunotherapy-based combinations
Latest Information Update: 19 Mar 2021
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Mar 2021 New trial record
- 13 Feb 2021 Results assessing (Data cut off; 9/1/2020) association of the baseline neutrophil to eosinophil ratio (NER) with outcomes to immunotherapy-based combination treatment in metastatic renal cell carcinoma, presented at the 2021 Genitourinary Cancers Symposium.